

GP. 1642

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Dunstan

Serial No.: 09/389,545

Group Art Unit No.: 1642

Filed: September 3, 1999

Examiner: Helms, L

For: Compositions and Methods for the Prevention or Treatment
of Cancer and Bone Loss Associated with Cancer

Docket No.: A-605

RECEIVED
JAN 28 2000

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, DC 20231

Sir:


As a means of complying with the duty of disclosure, applicant submits a "List of References Cited by Applicant" on a modified PTO-1449 form and provide a copy of each of the listed references for consideration by the Examiner.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

Applicant requests consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Respectfully submitted,


Robert B. Winter
Attorney/Agent for Applicant(s)
Registration No.: 34,458
Phone: (805) 447-2425
Date: JANUARY 18, 2000

Please send all future correspondence to:
U.S. Patent Operations/ RBW
Dept. 430, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1789

RECEIVED
JAN 20 2000

RECEIVED
JAN 28 2000

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, DC 20231, on the date appearing below.

1-18-2000

Date



Signature



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Dunstan

Serial No.: 09/389,545

Group Art Unit No.: 1642

Filed: September 3, 1999

Examiner: Helms, L

For: Compositions and Methods for the Prevention or Treatment
of Cancer and Bone Loss Associated with Cancer

Docket No.: A-605

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

As a means of complying with the duty of disclosure, applicant submits a "List of References Cited by Applicant" on a modified PTO-1449 form and provide a copy of each of the listed references for consideration by the Examiner.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

Applicant requests consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Respectfully submitted,

Robert B. Winter
Attorney/Agent for Applicant(s)
Registration No.: 34,458
Phone: (805) 447-2425
Date: *JANUARY 18, 2000*

Please send all future correspondence to:
U.S. Patent Operations/ RBW
Dept. 430, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1789

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, DC 20231, on the date appearing below.

1-14-2000

Date

Allen Sorenson

Signature